Satellos Bioscience Inc.
TSX:MSCL.TOBiotechnology
+$0.01 today
- Market cap
- $182.89M
- Beta
- 1.17
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$0.32
Volume 0.01M
Average 0.02M
MSCL.TO Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Satellos Bioscience Inc.TSX: MSCL.TO
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income grows 56.5% year over year
Q1 FY2026 net income of $9.61M (cash outflow) rose 56.5% year over year. Sequentially, it rose 29.6% from the prior quarter. Over 3 fiscal years it compounded at +30.8% a year.
Context
- Net income grew in size in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate of -$32.91M (+30.0%) for the fiscal year ending Dec 2026, a step up from the -9.9% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$9.61M+29.6% QoQ
- Last fiscal yearDec 2025
- -$25.31M-9.9% YoY
- LTMMar 2026
- -$28.45M— YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +56.5% | +67.6% | +11.1 pp |
| 1 year | -9.9% | +30.0% | +40.0 pp |
| 3-year CAGR | +30.8% | +5.5% | -25.2 pp |
| 5-year CAGR | -18.1% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
Mixed currencies · from the cash flow
- Latest · FY2025
- (25.31M) USD
- Year-over-year change
- —
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (25.31M) | — |
| FY2024 | 2024-12-31 | (28.1M) | -76.8% |
| FY2023 | 2023-12-31 | (15.89M) | -40.3% |
| FY2022 | 2022-12-31 | (11.32M) | +27.0% |
| FY2021 | 2021-12-31 | (15.51M) | — |
Net Income vs competitors
How MSCL.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Over three fiscal years its annual growth of +30.8% compares with a peer median of -7.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CA$36.35M CAD | +1.6% | +3.0% | — | |
MSCL.TOSatellos Bioscience Inc. | LTM Mar 2026 | $28.45M USD | — | +30.8% | — |
| LTM Apr 2026 | CA$11.83M CAD | -46.2% | -13.6% | — | |
| LTM Apr 2026 | CA$3.32M CAD | -65.1% | -7.4% | — | |
| Peer median (excluding MSCL.TO) | — | -46.2% | -7.4% | — | |
Competitors are the stored peer set for MSCL.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 · CAD | FY2022 Dec 2022 · CAD | FY2023 Dec 2023 · CAD | FY2024 Dec 2024 · CAD | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Net Income | (15.51M) | (11.32M) | (15.89M) | (28.1M) | (25.31M) |
| Depreciation & Amortization | 165.69K | 337K | 7K | 20K | 4K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 971.53K | 1.44M | 2.17M | 2.11M | 3.24M |
| Change in Working Capital | (485.64K) | 991K | 369K | (1.03M) | (1.5M) |
| Accounts Receivables | (67.4K) | 267.55K | (323K) | (43K) | 66.14K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (390.47K) | 726.11K | 0 | 0 | 0 |
| Other Working Capital | (27.77K) | (1.93K) | 692K | (982K) | (1.57M) |
| Other Non-Cash Items | 9.82M | 2.91M | (1.07M) | 2.02M | (435.77K) |
| Operating Cash Flow | (5.03M) | (5.78M) | (14.5M) | (24.98M) | (24.01M) |
| Capital Expenditures | (7.25K) | (3K) | (18K) | (6K) | (6.1K) |
| Acquisitions (Net) | 1.75M | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (17.52M) | (37.34M) | (23.78M) |
| Sales of Investments | 0 | 0 | 0 | 43.68M | 14.2M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 1.74M | (3K) | (17.54M) | 6.34M | (9.58M) |
| Debt Repayment | 186.57K | 0 | (284K) | 0 | 0 |
| Common Stock Issued | 7.08M | 2.78M | 32.46M | 42.8M | 2.28M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 185.46K | 0 | 18.85M | 10.68M | 0 |
| Financing Cash Flow | 7.45M | 2.78M | 51.03M | 53.49M | 2.28M |
| Effect of Forex Changes | (1.44K) | (76K) | 1.15M | 744K | (890.45K) |
| Net Change in Cash | 4.15M | (2.95M) | 20.14M | 35.59M | (32.2M) |
| Free Cash Flow | (5.04M) | (5.79M) | (14.52M) | (24.98M) | (24.02M) |
Satellos Bioscience Inc.
TSX:MSCL.TO
Intrinsic Alpha fair value
Locked
Current Price
$8.62
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.